Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.
The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.
Galectin Therapeutics Inc. director Richard A. Zordani Jr. reported a grant of stock options on common shares. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Zordani beneficially owns 60,000 derivative securities directly in the form of these options, providing potential future ownership of the same number of Galectin common shares if exercised.
Galectin Therapeutics reported new equity awards to its Chief Medical Officer, Jamil Khurram. On January 16, 2026, Khurram received stock options covering 65,000 shares of common stock with an exercise price of $3.04 per share, expiring on January 16, 2036. These options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027 and December 31, 2027.
On the same date, Khurram was also granted 100,000 Restricted Stock Units under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. Both awards are reported as directly owned.
Galectin Therapeutics director Kevin D. Freeman reported a new stock option award. On January 16, 2026, he was granted a stock option (right to buy) covering 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share.
The option was issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026. Following this grant, Freeman beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics director Kary Eldred received a new stock option grant. On January 16, 2026, Eldred was awarded options to purchase 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share. These options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026, meaning they become fully exercisable on that date. The options expire on January 16, 2036 if not exercised. Following this grant, Eldred beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics Inc. reported new equity awards for its President and CEO, Lewis Joel, who also serves as a director. On January 16, 2026, he was granted 84,000 stock options with an exercise price of $3.04 per share under the company’s 2019 Omnibus Equity Incentive Plan. The options vest in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, Joel also received 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. Each vested RSU converts into one share of Galectin common stock.
Galectin Therapeutics Inc. Chief Financial Officer Jack W. Callicutt reported new equity awards from the company. On January 16, 2026, he received a stock option for 65,000 shares of common stock at an exercise price of $3.04 per share, expiring on January 16, 2036. The options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, he was also granted 100,000 Restricted Stock Units. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. All awards were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, and are reported as directly owned by the officer.
Galectin Therapeutics Inc. granted stock options to a board member. Director Harold H. Shlevin received stock options covering 60,000 shares of Galectin Therapeutics common stock on January 16, 2026. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and expire on January 16, 2036. The options vest 100% on December 31, 2026, meaning Shlevin must remain eligible through that date before they become fully exercisable. Following this grant, he beneficially owns 60,000 derivative securities, held directly.
Galectin Therapeutics Inc. director Gilbert S. Omenn reported receiving a grant of derivative securities in the form of stock options. On January 16, 2026, he was awarded 60,000 stock options (right to buy) with a stated exercise price of $0 per share, all held in a direct ownership capacity. Following this grant, he beneficially owned 60,000 derivative securities linked to the company’s common stock. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and are scheduled to vest 100% on December 31, 2026, meaning they become fully exercisable on that date.
Galectin Therapeutics (GALT) director granted stock options
Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026. The options have an exercise price of $3.04 per share and were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. According to the filing, the options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Amelio beneficially owns 60,000 stock options directly.